These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

267 related items for PubMed ID: 25607641

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. WW domain-containing protein YAP associates with ErbB-4 and acts as a co-transcriptional activator for the carboxyl-terminal fragment of ErbB-4 that translocates to the nucleus.
    Komuro A, Nagai M, Navin NE, Sudol M.
    J Biol Chem; 2003 Aug 29; 278(35):33334-41. PubMed ID: 12807903
    [Abstract] [Full Text] [Related]

  • 3. Structural features and ligand binding properties of tandem WW domains from YAP and TAZ, nuclear effectors of the Hippo pathway.
    Webb C, Upadhyay A, Giuntini F, Eggleston I, Furutani-Seiki M, Ishima R, Bagby S.
    Biochemistry; 2011 Apr 26; 50(16):3300-9. PubMed ID: 21417403
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Using molecular repertoires to identify high-affinity peptide ligands of the WW domain of human and mouse YAP.
    Linn H, Ermekova KS, Rentschler S, Sparks AB, Kay BK, Sudol M.
    Biol Chem; 1997 Jun 26; 378(6):531-7. PubMed ID: 9224934
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Biophysical studies and NMR structure of YAP2 WW domain - LATS1 PPxY motif complexes reveal the basis of their interaction.
    Verma A, Jing-Song F, Finch-Edmondson ML, Velazquez-Campoy A, Balasegaran S, Sudol M, Sivaraman J.
    Oncotarget; 2018 Jan 30; 9(8):8068-8080. PubMed ID: 29487715
    [Abstract] [Full Text] [Related]

  • 10. Both TEAD-binding and WW domains are required for the growth stimulation and oncogenic transformation activity of yes-associated protein.
    Zhao B, Kim J, Ye X, Lai ZC, Guan KL.
    Cancer Res; 2009 Feb 01; 69(3):1089-98. PubMed ID: 19141641
    [Abstract] [Full Text] [Related]

  • 11. Angiomotins stimulate LATS kinase autophosphorylation and act as scaffolds that promote Hippo signaling.
    Mana-Capelli S, McCollum D.
    J Biol Chem; 2018 Nov 23; 293(47):18230-18241. PubMed ID: 30266805
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Characterization of the WW domain of human yes-associated protein and its polyproline-containing ligands.
    Chen HI, Einbond A, Kwak SJ, Linn H, Koepf E, Peterson S, Kelly JW, Sudol M.
    J Biol Chem; 1997 Jul 04; 272(27):17070-7. PubMed ID: 9202023
    [Abstract] [Full Text] [Related]

  • 18. YAP modifies cancer cell sensitivity to EGFR and survivin inhibitors and is negatively regulated by the non-receptor type protein tyrosine phosphatase 14.
    Huang JM, Nagatomo I, Suzuki E, Mizuno T, Kumagai T, Berezov A, Zhang H, Karlan B, Greene MI, Wang Q.
    Oncogene; 2013 Apr 25; 32(17):2220-9. PubMed ID: 22689061
    [Abstract] [Full Text] [Related]

  • 19. Tumor suppressor LATS1 is a negative regulator of oncogene YAP.
    Hao Y, Chun A, Cheung K, Rashidi B, Yang X.
    J Biol Chem; 2008 Feb 29; 283(9):5496-509. PubMed ID: 18158288
    [Abstract] [Full Text] [Related]

  • 20. Structural basis of YAP recognition by TEAD4 in the hippo pathway.
    Chen L, Chan SW, Zhang X, Walsh M, Lim CJ, Hong W, Song H.
    Genes Dev; 2010 Feb 01; 24(3):290-300. PubMed ID: 20123908
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 14.